MAPK3 and prostate carcinoma: Some other findings showed that the tested compounds exerted the inhibitory effect on prostate cancer cell metastasis mainly by inhibiting the VEGFR-2 signaling pathway, regulating the Notch-1 signaling pathway, downregulating FAK, c-Src, and NF-κB pathways, repressing the CCL2–STAT3 axis, and suppressing MMP-2/-9 expression via AKT–mTOR and ROS–ERK1/2 pathways.